Johnny Chang, MD
Urology · Torrington, CTNPI 1619975182
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Gyrus ACMI, Inc. at 48.9% of the total. 2025 is the largest year on record at $2,674, more than ten times the $88 reported in 2019.
Across 127 payments — averaging $42.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gyrus ACMI, Inc.$3K
- Sumitomo Pharma America, Inc.$483
- Astellas Pharma US Inc$404
- Urovant Sciences Inc$309
- Pfizer$265
- Acerus Pharmaceuticals Corporation$237
- plus $1K from 18 others
What the payments were for
- Consulting fees$2,63049%
- Food & beverage$2,37844%
- Education$3667%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gyrus ACMI, Inc. | 2 | $2,630 |
| Sumitomo Pharma America, Inc. | 26 | $483 |
| Astellas Pharma US Inc | 10 | $404 |
| Urovant Sciences Inc | 21 | $309 |
| Pfizer | 8 | $265 |
| Acerus Pharmaceuticals Corporation | 13 | $237 |
| Antares Pharma, Inc. | 8 | $175 |
| Dentsply IH Inc. | 6 | $98 |
| Regeneron Healthcare Solutions, Inc. | 1 | $97 |
| Teleflex LLC | 4 | $92 |
| Boston Scientific | 4 | $86 |
| Merck | 4 | $81 |
| Axonics, Inc. | 4 | $72 |
| Halozyme Inc | 3 | $59 |
| Tolmar, Inc. | 2 | $58 |
| Myovant Sciences Inc. | 2 | $53 |
| Hollister Incorporated | 2 | $35 |
| 180 Medical, Inc. | 1 | $30 |
| Medtronic | 1 | $28 |
| BD | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $15 |
| Photocure Inc | 1 | $14 |
| Sagent Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Soltive$2,630
How this compares
$5,374 in reported general payments places this provider in the 70th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 277 | $216,941 |
| GemtesaVibegron | 179 | $183,920 |
| OrgovyxRelugolix | 18 | $49,552 |
| Dutasteride | 781 | $26,120 |
| Finasteride | 1,970 | $23,359 |
| Mirabegron ErMirabegron | 28 | $18,677 |
| Tamsulosin Hcl | 1,240 | $17,080 |
| Oxybutynin Chloride ErOxybutynin Chloride | 523 | $10,418 |
| Methenamine Hippurate | 151 | $9,360 |
| LithostatAcetohydroxamic Acid | 12 | $4,761 |
| Testosterone | 46 | $4,718 |
| Solifenacin Succinate | 120 | $3,796 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 94 | $2,651 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 26 | $2,352 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 16 | $1,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $483 | $233,472197 claims |
| Astellas Pharma US IncMyrbetriq | $404 | $216,941277 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 156 urology providers in Connecticut.
Other urology in Torrington
- Mary SoysterTorrington$58K
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
- Stanton HonigNew Haven$40K
- Joshua SteinNew Britain$30K
- Steven ShichmanHartford$28K
- Christine LiawBridgeport$27K
- David CrawleyNew London$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.